Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study

Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. Thus, there is an urgent need for safe and effective novel therapies. PDAC’s excessive reliance on glucose metabolism for its metabolic needs provides a target for metabolic therapy. Preclinical PDAC models have demo...

Full description

Bibliographic Details
Main Authors: Lauren K. Park, Kian-Huat Lim, Jonas Volkman, Mina Abdiannia, Hannah Johnston, Zack Nigogosyan, Marilyn J. Siegel, Janet B. McGill, Alexis M. McKee, Maamoun Salam, Rong M. Zhang, Da Ma, Karteek Popuri, Vincent Tze Yang Chow, Mirza Faisal Beg, William G. Hawkins, Linda R. Peterson, Joseph E. Ippolito
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Cancer & Metabolism
Subjects:
Pancreatic ductal adenocarcinoma
Safety
Efficacy
Sodium-glucose cotransporter-2 inhibitor
SGLT2
Dapagliflozin
Online Access:https://doi.org/10.1186/s40170-023-00306-2

Internet

https://doi.org/10.1186/s40170-023-00306-2

Similar Items